Clinical Trial

Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated August 6, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Cross-over, 2-sequence, 2-treatment, 2-period single-centre, phase IV, randomized, open label study.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-08-27; most recent amendment 2025-08-05.
Trial Details
NCT Number NCT06578520
Lead Sponsor Fundación para la Investigación del Hospital Clínico de Valencia
Conditions Heart Failure
Enrollment 31 participants
Start Date 2024-07-30
Primary Completion 2025-12-01 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-06